Heska Corporation (HSKA) Position Lowered by Teton Advisors Inc.
Teton Advisors Inc. lowered its position in shares of Heska Corporation (NASDAQ:HSKA) by 12.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,000 shares of the medical research company’s stock after selling 1,500 shares during the period. Teton Advisors Inc. owned 0.15% of Heska Corporation worth $1,123,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC purchased a new position in Heska Corporation during the first quarter worth $257,000. Arxis Securities LLC purchased a new position in Heska Corporation during the first quarter worth $377,000. Texas Permanent School Fund purchased a new position in Heska Corporation during the first quarter worth $272,000. BNP Paribas Arbitrage SA raised its position in Heska Corporation by 1,306.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,167 shares of the medical research company’s stock worth $123,000 after buying an additional 1,084 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Heska Corporation by 29.6% in the first quarter. Bank of New York Mellon Corp now owns 202,552 shares of the medical research company’s stock worth $21,264,000 after buying an additional 46,231 shares during the last quarter. 79.81% of the stock is currently owned by institutional investors.
Shares of Heska Corporation (NASDAQ HSKA) opened at 97.79 on Monday. The firm has a 50-day moving average of $101.39 and a 200 day moving average of $96.52. The company has a market cap of $706.63 million, a price-to-earnings ratio of 49.84 and a beta of 0.82. Heska Corporation has a 12 month low of $46.51 and a 12 month high of $115.00.
Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $34.30 million for the quarter, compared to the consensus estimate of $33.35 million. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.35 EPS. On average, analysts expect that Heska Corporation will post $2.04 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Heska Corporation (HSKA) Position Lowered by Teton Advisors Inc.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/21/heska-corporation-hska-position-lowered-by-teton-advisors-inc.html.
A number of research firms recently weighed in on HSKA. Aegis raised their price target on shares of Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a research report on Tuesday, August 1st. B. Riley reaffirmed a “neutral” rating and issued a $85.00 price objective on shares of Heska Corporation in a research report on Friday, July 28th. Benchmark Co. reaffirmed a “buy” rating and issued a $120.00 price objective (up previously from $106.00) on shares of Heska Corporation in a research report on Wednesday, August 9th. BidaskClub raised shares of Heska Corporation from a “hold” rating to a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research raised shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price objective on the stock in a research report on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $105.20.
In other news, EVP Steve Asakowicz sold 382 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $100.08, for a total transaction of $38,230.56. Following the sale, the executive vice president now owns 10,382 shares of the company’s stock, valued at approximately $1,039,030.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carol Wrenn sold 1,630 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $96.95, for a total transaction of $158,028.50. Following the sale, the director now directly owns 6,174 shares in the company, valued at approximately $598,569.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,265 shares of company stock worth $2,983,439. Insiders own 14.70% of the company’s stock.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.